ABVC BioPharma Report Updated by Zacks/SCR
ABVC BioPharma, a clinical-stage biopharmaceutical company, announced an update report by Zacks Small Cap Research on Aug. 30, 2021. The company is developing six drug candidates and one medical device (Vitargus®) targeting oncology/hematology and CNS. ABVC collaborates with renowned institutions like Stanford for its clinical trials, aiming for Phase III trials globally for Vitargus®. The press release includes forward-looking statements, emphasizing uncertainties in clinical development and regulatory approval, alongside risks of competition and manufacturing challenges.
- Collaboration with reputable institutions for clinical trials.
- Active development of six drugs and one medical device.
- Uncertainties surrounding clinical trial outcomes.
- Risks associated with manufacturing at a commercial scale.
- Potential difficulties in securing regulatory approval.
FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Zacks Small Cap Research has issued an update report on the company which may be accessed at:
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). For Vitargus®, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.
Forward-Looking Statements
Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact:
Andy An – Chief Financial Officer
765-610-8826
andyan@ambrivis.com
FAQ
What recent update did ABVC BioPharma announce on Aug. 30, 2021?
What is the focus of ABVC BioPharma's drug development?
What is the significance of Vitargus® in ABVC BioPharma's portfolio?
What are the clinical trial collaborations for ABVC BioPharma?
What risks did ABVC BioPharma mention in their press release?
